Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present KalVista Pharmaceuticals, Inc. (NASDAQ: KALV).

Full DD Report for KALV

You must become a subscriber to view this report.


Recent News from (NASDAQ: KALV)

KalVista Pharmaceuticals prices public offering of common stock
KalVista Pharmaceuticals (NASDAQ: KALV ) prices its public offering of 4M shares of common stock at a price to the public of $17.00 per share for gross proceeds of ~$68M. More news on: Kalvista Pharmaceuticals, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: September, 06 2018 09:30
KalVista Pharmaceuticals Announces Pricing of Public Offering of Common Stock
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at...
Source: Business Wire
Date: September, 06 2018 09:15
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, announced today that it intends to offer shares of its common stock in an underwritten public offering. In...
Source: Business Wire
Date: September, 05 2018 16:02
Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), IZEA Inc. (NASDAQ:IZEA), So...
Source: GlobeNewswire
Date: August, 27 2018 07:45
FDA OKs Shire's Takhzyro for HAE
The FDA approves Shire plc's (NASDAQ: SHPG ) TAKHZYRO (lanadelumab-flyo) for the prevention of attacks of hereditary angioedema (HAE) in patients at least 12 years old. More news on: Shire PLC, Adverum Biotechnologies, Inc., BioCryst Pharmaceuticals, Inc., Healthcare stocks news, Rea...
Source: SeekingAlpha
Date: August, 23 2018 22:43
KalVista Pharmaceuticals advancing pipeline; $14.6M raised; shares up 4%
KalVista Pharmaceuticals ( KALV +4.3% ) will be moving KVD900 forward as a potential on-demand therapy for acute HAE attacks, based upon Phase 1 trial data. A Phase 2 clinical trial should launch before year-end. More news on: Kalvista Pharmaceuticals, Healthcare stocks news, Stocks on t...
Source: SeekingAlpha
Date: July, 31 2018 10:20
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
– KVD900 Selected to Advance to Phase 2 as Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema (HAE) – – KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME) Enrollment Remains on Track with Data Expected in...
Source: Business Wire
Date: July, 31 2018 07:00
Recent Analysis Shows Cigna, Basic Energy Services, KalVista Pharmaceuticals, QuinStreet, Armstrong World Industries, and NMI Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cigna Corporation (NYSE:CI), Basic Energy Services, Inc. (NYSE:BAS), KalV...
Source: GlobeNewswire
Date: June, 25 2018 07:35
KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
– KVD900 Data Accepted for Late Breaking Poster Session – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data from ...
Source: Business Wire
Date: May, 29 2018 07:30
KalVista Pharmaceuticals Recognizes HAE Day
– A Global Awareness Day for a Rare Life-Threatening Condition – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced rec...
Source: Business Wire
Date: May, 16 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0818.1917.5418.1917.01590,579
2018-05-178.978.859.028.659138,132

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0711,44889,05512.8550Cover
2018-12-061,57630,3365.1951Cover
2018-12-046,06338,28015.8386Cover
2018-12-0310,38116,61462.4834Short
2018-11-305,91017,29334.1757Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on KALV.


About KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)

Logo for KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $97,378,973 - 05/11/2018
  • Issue and Outstanding: 10,795,895 - 03/01/2018

 


Recent Filings from (NASDAQ: KALV)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 16 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 13 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 14 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: December, 14 2017
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: November, 13 2017
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: October, 20 2017

 

 


Daily Technical Chart for (NASDAQ: KALV)

Daily Technical Chart for (NASDAQ: KALV)


Stay tuned for daily updates and more on (NASDAQ: KALV)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: KALV)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in KALV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of KALV and does not buy, sell, or trade any shares of KALV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/